Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis: results from an open-label extension study

Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis

(2020) Lisa A. Beck et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Laboratory safety of dupilumab in moderate‐to‐severe atopic dermatitis: results from three phase III trials ( LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS )

(2019) A. Wollenberg et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis

(2019) Eric L. Simpson et al.   JAMA Dermatology

Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t

(2018) M. de Bruin-Weller et al.   BRITISH JOURNAL OF DERMATOLOGY

Patients with Atopic Dermatitis Colonized with Staphylococcus aureus Have a Distinct Phenotype and Endotype

(2018) Eric L. Simpson et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II

(2018) A. Wollenberg et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council

(2017) Eric L. Simpson et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

(2017) Andrew Blauvelt et al.   LANCET

Japanese guidelines for atopic dermatitis 2017

(2017) Ichiro Katayama et al.   ALLERGOLOGY INTERNATIONAL

Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging Therapies

(2017) Mark Boguniewicz et al.   Journal of Allergy and Clinical Immunology-In Practice

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

(2016) Eric L. Simpson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Biomarkers for atopic dermatitis

(2015) Judith Thijs et al.   Current Opinion in Allergy and Clinical Immunology

Guidelines of care for the management of atopic dermatitis

(2014) Robert Sidbury et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes

(2014) L. E. Macdonald et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice

(2014) A. J. Murphy et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Association of serum interleukin-18 and other biomarkers with disease severity in adults with atopic dermatitis

(2011) Kenzen Kou et al.   ARCHIVES OF DERMATOLOGICAL RESEARCH